The role of WT1 in oncogenesis

Tumor suppressor or oncogene?

David M. Loeb, Saraswati Sukumar

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Although originally identified as a tumor suppressor gene, WT1 is overexpressed in a variety of hematologic malignancies and solid tumors, including acute leukemia, breast cancer, malignant mesothelioma, renal cell carcinoma, and others. Overexpression of both wild-type and mutant WT1 has been reported. In some cases, this finding represents overexpression of a gene that should be expressed at lower levels, but in other cases, WT1 is expressed at high levels in a tissue type in which there is normally no expression at all. In this review, the mechanisms of altered WT1 expression are explored, including changes in promoter methylation. WT1 target genes that may be important for oncogenesis are discussed, as is the use of WT1 expression as a diagnostic tool. The prognostic implications of altered WT1 expression and the potential for immunotherapy aimed at WT1 are also discussed.

Original languageEnglish (US)
Pages (from-to)117-126
Number of pages10
JournalInternational Journal of Hematology
Volume76
Issue number2
DOIs
StatePublished - Aug 1 2002
Externally publishedYes

Fingerprint

Oncogenes
Carcinogenesis
Hematologic Neoplasms
Tumor Suppressor Genes
Renal Cell Carcinoma
Immunotherapy
Methylation
Genes
Neoplasms
Leukemia
Breast Neoplasms
Malignant Mesothelioma

Keywords

  • Breast cancer
  • Leukemia
  • Mesothelioma
  • Transcription factor
  • Wilms' tumor

ASJC Scopus subject areas

  • Hematology

Cite this

The role of WT1 in oncogenesis : Tumor suppressor or oncogene? / Loeb, David M.; Sukumar, Saraswati.

In: International Journal of Hematology, Vol. 76, No. 2, 01.08.2002, p. 117-126.

Research output: Contribution to journalArticle

@article{fd5ec176b72b4ee9a278220e9a86b518,
title = "The role of WT1 in oncogenesis: Tumor suppressor or oncogene?",
abstract = "Although originally identified as a tumor suppressor gene, WT1 is overexpressed in a variety of hematologic malignancies and solid tumors, including acute leukemia, breast cancer, malignant mesothelioma, renal cell carcinoma, and others. Overexpression of both wild-type and mutant WT1 has been reported. In some cases, this finding represents overexpression of a gene that should be expressed at lower levels, but in other cases, WT1 is expressed at high levels in a tissue type in which there is normally no expression at all. In this review, the mechanisms of altered WT1 expression are explored, including changes in promoter methylation. WT1 target genes that may be important for oncogenesis are discussed, as is the use of WT1 expression as a diagnostic tool. The prognostic implications of altered WT1 expression and the potential for immunotherapy aimed at WT1 are also discussed.",
keywords = "Breast cancer, Leukemia, Mesothelioma, Transcription factor, Wilms' tumor",
author = "Loeb, {David M.} and Saraswati Sukumar",
year = "2002",
month = "8",
day = "1",
doi = "10.1007/BF02982573",
language = "English (US)",
volume = "76",
pages = "117--126",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - The role of WT1 in oncogenesis

T2 - Tumor suppressor or oncogene?

AU - Loeb, David M.

AU - Sukumar, Saraswati

PY - 2002/8/1

Y1 - 2002/8/1

N2 - Although originally identified as a tumor suppressor gene, WT1 is overexpressed in a variety of hematologic malignancies and solid tumors, including acute leukemia, breast cancer, malignant mesothelioma, renal cell carcinoma, and others. Overexpression of both wild-type and mutant WT1 has been reported. In some cases, this finding represents overexpression of a gene that should be expressed at lower levels, but in other cases, WT1 is expressed at high levels in a tissue type in which there is normally no expression at all. In this review, the mechanisms of altered WT1 expression are explored, including changes in promoter methylation. WT1 target genes that may be important for oncogenesis are discussed, as is the use of WT1 expression as a diagnostic tool. The prognostic implications of altered WT1 expression and the potential for immunotherapy aimed at WT1 are also discussed.

AB - Although originally identified as a tumor suppressor gene, WT1 is overexpressed in a variety of hematologic malignancies and solid tumors, including acute leukemia, breast cancer, malignant mesothelioma, renal cell carcinoma, and others. Overexpression of both wild-type and mutant WT1 has been reported. In some cases, this finding represents overexpression of a gene that should be expressed at lower levels, but in other cases, WT1 is expressed at high levels in a tissue type in which there is normally no expression at all. In this review, the mechanisms of altered WT1 expression are explored, including changes in promoter methylation. WT1 target genes that may be important for oncogenesis are discussed, as is the use of WT1 expression as a diagnostic tool. The prognostic implications of altered WT1 expression and the potential for immunotherapy aimed at WT1 are also discussed.

KW - Breast cancer

KW - Leukemia

KW - Mesothelioma

KW - Transcription factor

KW - Wilms' tumor

UR - http://www.scopus.com/inward/record.url?scp=0012645205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0012645205&partnerID=8YFLogxK

U2 - 10.1007/BF02982573

DO - 10.1007/BF02982573

M3 - Article

VL - 76

SP - 117

EP - 126

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -